Flubromazolam is not recognised to acquire any therapeutic use, will not be to the WHO Model Listing of Crucial Medicines and hasn't been marketed as a medicinal product. While specified NPS belonging into the BZD course have pharmacological profiles similar to controlled pharmaceutical B